Critical role of tedizolid in the treatment of acute bacterial skin and skin structure infections

References

• U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)Guidance for Industry Acute Bacterial Skin and Skin Structure Infections: Developing Drugs for TreatmentSilver Spring, MDUS Food and Drug Administration2013 Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guid-ances/ucm071185.pdfAccessed May 1, 2016
   Google Scholar
• PallinDJEganDJPelletierAJEspinolaJAHooperDCCamargoCAJrIncreased US emergency department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of community-associated methicillin-resistant Staphylococcus aureusAnn Emerg Med2008513 291 29818222564
   PubMed Web of Science ®Google Scholar
• MoranGJKrishnadasanAGorwitzRJMethicillin-resistant Saureus infections among patients in the emergency departmentN Engl J Med20063557 666 67416914702
   PubMed Web of Science ®Google Scholar
• TalanDAKrishnadasanAGorwitzRJComparison of Staphylococcus aureus from skin and soft-tissue infections in US emergency department patients, 2004 and 2008Clin Infect Dis2011532 144 14921690621
   PubMed Web of Science ®Google Scholar
• MoranGJAmiiRNAbrahamianFMTalanDAMethicillin-resistant Staphylococcus aureus in community-acquired skin infectionsEmerg Infect Dis2005116 928 93015963289
   PubMed Web of Science ®Google Scholar
• BassettiMBaguneidMBouzaEDrydenMNathwaniDWilcoxMEuropean perspective and update on the management of complicated skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolidClin Microbiol Infect201420Suppl 4 3 1824580738
   PubMed Web of Science ®Google Scholar
• MorrisseyILeakeyANorthwoodJBIn vitro activity of ceftaroline and comparator antimicrobials against European and Middle East isolates from complicated skin and skin-structure infections collected in 2008–2009Int J Antimicrob Agents2012403 227 23422796201
   PubMed Web of Science ®Google Scholar
• StevensDLBisnoALChambersHFPractice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of AmericaClin Infect Dis2014592 147 15924947530
   PubMed Web of Science ®Google Scholar
• CrottyMPKrekelTBurnhamCARitchieDJNew gram-positive agents: the next generation of oxazolidinones and lipoglycopeptidesJ Clin Microbiol2016
   Web of Science ®Google Scholar
• ShawKJBarbachynMRThe oxazolidinones: past, present, and futureAnn N Y Acad Sci20111241 48 7022191526
   PubMed Web of Science ®Google Scholar
• BaeSKYangSHShinKNRheeJKYooMLeeMGPharmacokinetics of DA-7218, a new oxazolidinone, and its active metabolite, DA-7157, after intravenous and oral administration of DA-7218 and DA-7157 to ratsJ Pharm Pharmacol2007597 955 96317637190
   PubMed Web of Science ®Google Scholar
• RybakJMRobertsKTedizolid phosphate: a next-generation oxazolidinoneInfect Dis Ther Epub2015224
   Google Scholar
• LockeJBZurenkoGEShawKJBartizalKTedizolid for the management of human infections: in vitro characteristicsClin Infect Dis201458Suppl 1 S35 S4224343830
   PubMed Web of Science ®Google Scholar
• ColcaJRMcDonaldWGWaldonDJCross-linking in the living cell locates the site of action of oxazolidinone antibioticsJ Biol Chem200327824 21972 2197912690106
   PubMed Web of Science ®Google Scholar
• KanafaniZACoreyGRTedizolid (TR-701): a new oxazolidinone with enhanced potencyExpert Opin Investig Drugs2012214 515 522
   PubMed Web of Science ®Google Scholar
• WilsonDNSchluenzenFHarmsJMStarostaALConnellSRFuciniPThe oxazolidinone antibiotics perturb the ribosomal peptidyltransferase center and effect tRNA positioningProc Natl Acad Sci U S A200810536 13339 1334418757750
   PubMed Web of Science ®Google Scholar
• LeachKLSwaneySMColcaJRThe site of action of oxazolidinone antibiotics in living bacteria and in human mitochondriaMol Cell2007263 393 40217499045
   PubMed Web of Science ®Google Scholar
• HuttunenKMRaunioHRautioJProdrugs – from serendipity to rational designPharmacol Rev2011633 750 77121737530
   PubMed Web of Science ®Google Scholar
• HeimbachTOhDMLiLYAbsorption rate limit considerations for oral phosphate prodrugsPharm Res2003206 848 85612817887
   PubMed Web of Science ®Google Scholar
• FlanaganSFangEMunozKAMinassianSLProkocimerPGSingle-and multiple-dose pharmacokinetics and absolute bioavailability of tedizolidPharmacotherapy2014349 891 90024989138
   PubMed Web of Science ®Google Scholar
• ChenRShenKChangXTanakaTHuPPharmacokinetics of 7-day multiple dose tedizolid phosphate in healthy chinese subjects [Abstract A-452]Poster presented at: 55th Interscience Conference on Antimicrobial Agents and ChemotheraphySeptember 17–21; 2015San Diego, CA
   Google Scholar
• TanakaTHayashiYOkumuraKOral bioavailability of tedizolid in healthy Japenese subjects in a phase I study [Abstract P1718]Poster presented at: European Congress of Clinical Microbiology and Infectious DiseasesMay 10–13; 2014Barcelona, Spain
   Google Scholar
• FlanaganSDBienPAMunozKAMinassianSLProkocimerPGPharmacokinetics of tedizolid following oral administration: single and multiple dose, effect of food, and comparison of two solid forms of the prodrugPharmacotherapy2014343 240 25023926058
   PubMed Web of Science ®Google Scholar
• FlanaganSPassarellJLuQFiedler-KellyJLudwigEProkocimerPTedizolid population pharmacokinetics, exposure response, and target attainmentAntimicrob Agents Chemother20145811 6462 647025136028
   PubMed Web of Science ®Google Scholar
• StalkerDJJungbluthGLClinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterialClin Pharmacokinet20034213 1129 114014531724
   PubMed Web of Science ®Google Scholar
• StalkerDJJungbluthGLHopkinsNKBattsDHPharmacokinetics and tolerance of single- and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteersJ Antimicrob Chemother2003515 1239 124612668582
   PubMed Web of Science ®Google Scholar
• HousmanSTPopeJSRussomannoJPulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteersAntimicrob Agents Chemother2012565 2627 263422330925
   PubMed Web of Science ®Google Scholar
• SahreMSabarinathSGrantMSkin and soft tissue concentrations of tedizolid (formerly torezolid), a novel oxazolidinone, following a single oral dose in healthy volunteersInt J Antimicrob Agents2012401 51 5422584101
   PubMed Web of Science ®Google Scholar
• OngVFlanaganSFangEAbsorption, distribution, metabolism, and excretion of the novel antibacterial prodrug tedizolid phosphateDrug Metab Dispos2014428 1275 128424875463
   PubMed Web of Science ®Google Scholar
• KennedyGOsbornJFlanaganSAlsayedNBertolamiSStability of crushed tedizolid phosphate tablets for nasogastric tube administrationDrugs R D2015154 329 33326416654
   PubMedGoogle Scholar
• BradleyJSFlanaganSDArrietaACJacobsRCapparelliEProkocimerPPharmacokinetics, safety and tolerability of single oral or intravenous administration of 200 mg tedizolid phosphate in adolescentsPediatr Infect Dis J2016356 628 63326910588
   PubMed Web of Science ®Google Scholar
• KearnsGLAbdel-RahmanSMBlumerJLSingle dose pharmacokinetics of linezolid in infants and childrenPediatr Infect Dis J20001912 1178 118411144380
   PubMed Web of Science ®Google Scholar
• DreskinHMuñozKAFangESafety and pharmacokinetics of single oral administration of tedizolid phosphate in healthy elderly subjects and adult control subjects [Abstract A-1293]Poster presented at: 52nd Interscience Conference on Antimicrobial Agents and ChemotheraphySeptember 9–12; 2012San Francisco, CA
   Google Scholar
• FlanaganSMinassianSLPassarellJFiedler-KellyJProkocimerPTedizolid plasma pharmacokinetics are comparable in obese and non-obese patients and healty patients [Abstract P1703]Poster presented at: European Congress of Clinical Microbiology and Infectious DiseasesMay 10–13 2014Barcelona, Spain
   Google Scholar
• BhalodiAAPapasavasPKTishlerDSNicolauDPKutiJLPharmacokinetics of intravenous linezolid in moderately to morbidly obese adultsAntimicrob Agents Chemother2013573 1144 114923254421
   PubMed Web of Science ®Google Scholar
• HamiltonRThaiXCAmeriDPaiMPOral bioavailability of linezolid before and after Roux-en-Y gastric bypass surgery: is dose modification necessary in obese subjects?J Antimicrob Chemother2013683 666 67323160755
   PubMed Web of Science ®Google Scholar
• Lopez-GarciaBLuqueSRobertsJAGrauSPharmacokinetics and preliminary safety of high dose linezolid for the treatment of gram-positive bacterial infectionsJ Infect2015715 604 60726099449
   PubMed Web of Science ®Google Scholar
• FlanaganSMinassianSLMorrisDPharmacokinetics of tedizolid in subjects with renal or hepatic impairmentAntimicrob Agents Chemother20145811 6471 647625136024
   PubMed Web of Science ®Google Scholar
• LeveyASCoreshJGreeneTUsing standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rateAnn Intern Med20061454 247 25416908915
   PubMed Web of Science ®Google Scholar
• MacGowanAPPharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infectionsJ Antimicrob Chemother200351Suppl 2 ii17 ii2512730139
   PubMed Web of Science ®Google Scholar
• BrierMEStalkerDJAronoffGRPharmacokinetics of linezolid in subjects with renal dysfunctionAntimicrob Agents Chemother2003479 2775 278012936973
   PubMed Web of Science ®Google Scholar
• NukuiYHatakeyamaSOkamotoKHigh plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopeniaJ Antimicrob Chemother2013689 2128 213323625638
   PubMed Web of Science ®Google Scholar
• Lopez-GarciaBLuqueSMasedaEGrauSComment on: pharmacokinetics of high dosage of linezolid in two morbidly obese patientsJ Antimicrob Chemother20157011 316826169559
   PubMed Web of Science ®Google Scholar
• MorataLCuestaMRojasJFRisk factors for a low linezolid trough plasma concentration in acute infectionsAntimicrob Agents Chemother2013574 1913 191723403416
   PubMed Web of Science ®Google Scholar
• FlanaganSProkocimerPReduction in tedizolid plasma exposure among end-stage renal disease patients undergoing dialysis is explained by variations in ideal body weightAntimicrob Agents Chemother2016605 3246 324726926636
   PubMed Web of Science ®Google Scholar
• HendershotPEJungbluthGLCammarataSKHopkinsNJPharmacokinetics of linezolid in patients with liver diseaseJ Antimicrob Chemother199944Suppl A 55
   Google Scholar
• LouieALiuWKulawyRDrusanoGLIn vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection modelAntimicrob Agents Chemother2011557 3453 346021502615
   PubMed Web of Science ®Google Scholar
• DrusanoGLLiuWKulawyRLouieAImpact of granulocytes on the antimicrobial effect of tedizolid in a mouse thigh infection modelAntimicrob Agents Chemother20115511 5300 530521911576
   PubMed Web of Science ®Google Scholar
• LodiseTPDrusanoGLUse of pharmacokinetic/pharmacodynamic systems analyses to inform dose selection of tedizolid phosphateClin Infect Dis201458Suppl 1 S28 S3424343829
   PubMed Web of Science ®Google Scholar
• Anti-infective drugs advisory committeeTedizolid Phosphate for the Treatment of Acute Bacterial Skin and Skin Structure InfectionsSilver Spring MDUS Food and Drug Administration2014 Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisory-Committee/UCM390790.pdfAccessed May 1, 2016
   Google Scholar
• The European Committee on Antimicrobial Susceptibility Testing (Eucast)Breakpoint tables for interpretation of MICs and zone diameters. Version 6.02016 Available from: http://www.eucast.orgAccessed May 21, 2016
   Google Scholar
• BrownSDTraczewskiMMComparative in vitro antimicrobial activities of torezolid (TR-700), the active moiety of a new oxazolidinone, torezolid phosphate (TR-701), determination of tentative disk diffusion interpretive criteria, and quality control rangesAntimicrob Agents Chemother2010545 2063 206920231392
   PubMed Web of Science ®Google Scholar
• SchaadtRSweeneyDShinabargerDZurenkoGIn vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agentAntimicrob Agents Chemother2009538 3236 323919528279
   PubMed Web of Science ®Google Scholar
• LeeYHongSKChoiSImWYongDLeeKIn vitro activity of tedizolid against gram-positive bacteria in patients with skin and skin structure infections and hospital-acquired pneumonia: a Korean multicenter studyAnn Lab Med2015355 523 53026206690
   PubMed Web of Science ®Google Scholar
• Schmidt-MalanSMGreenwood QuaintanceKEKarauMJPatelRIn vitro activity of tedizolid against staphylococci isolated from prosthetic joint infectionsDiagn Microbiol Infect Dis2016851 77 7926906190
   PubMed Web of Science ®Google Scholar
• SahmDFDeaneJBienPAResults of the surveillance of Tedizolid activity and resistance program: in vitro susceptibility of gram-positive pathogens collected in 2011 and 2012 from the United States and EuropeDiagn Microbiol Infect Dis2015812 112 11825488274
   PubMed Web of Science ®Google Scholar
• ChenHYangQZhangRIn vitro antimicrobial activity of the novel oxazolidinone tedizolid and comparator agents against Staphylococcus aureus and linezolid-resistant Gram-positive pathogens: a multicentre study in ChinaInt J Antimicrob Agents2014443 276 27725108879
   PubMed Web of Science ®Google Scholar
• ProkocimerPBienPDeandaCPillarCMBartizalKIn vitro activity and microbiological efficacy of tedizolid (TR-700) against Gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infectionsAntimicrob Agents Chemother2012569 4608 461322687509
   PubMed Web of Science ®Google Scholar
• ShorrAFLodiseTPCoreyGRAnalysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infectionsAntimicrob Agents Chemother2015592 864 87125421472
   PubMed Web of Science ®Google Scholar
• GonzalesRDSchreckenbergerPCGrahamMBKelkarSDenBestenKQuinnJPInfections due to vancomycin-resistant Enterococcus faecium resistant to linezolidLancet20013579263 117911323048
   PubMed Web of Science ®Google Scholar
• TsiodrasSGoldHSSakoulasGLinezolid resistance in a clinical isolate of Staphylococcus aureusLancet20013589277 207 20811476839
   PubMed Web of Science ®Google Scholar
• LockeJBHilgersMShawKJNovel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700)Antimicrob Agents Chemother20095312 5265 527419752277
   PubMed Web of Science ®Google Scholar
• Kosowska-ShickKJulianKGMcGheePLAppelbaumPCWhitenerCJMolecular and epidemiologic characteristics of linezolid-resistant coagulase-negative staphylococci at a tertiary care hospitalDiagn Microbiol Infect Dis2010681 34 3920727467
   PubMed Web of Science ®Google Scholar
• PournarasSNtokouEZarkotouOLinezolid dependence in Staphylococcus epidermidis bloodstream isolatesEmerg Infect Dis2013191 129 13223260390
   PubMed Web of Science ®Google Scholar
• KehrenbergCSchwarzSJacobsenLHansenLHVesterBA new mechanism for chloramphenicol, florfenicol and clindamycin resistance: methylation of 23S ribosomal RNA at A2503Mol Microbiol2005574 1064 107316091044
   PubMed Web of Science ®Google Scholar
• TohSMXiongLAriasCAAcquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolidMol Microbiol2007646 1506 151417555436
   PubMed Web of Science ®Google Scholar
• Silva-Del ToroSLGreenwood-QuaintanceKEPatelRIn vitro activity of tedizolid against linezolid-resistant staphylococci and enterococciDiagn Microbiol Infect Dis2016851 102 10426971179
   PubMed Web of Science ®Google Scholar
• BesierSLudwigAZanderJBradeVWichelhausTALinezolid resistance in Staphylococcus aureus: gene dosage effect, stability, fitness costs, and cross-resistancesAntimicrob Agents Chemother2008524 1570 157218212098
   PubMed Web of Science ®Google Scholar
• MarshallSHDonskeyCJHutton-ThomasRSalataRARiceLBGene dosage and linezolid resistance in Enterococcus faecium and Enterococcus faecalisAntimicrob Agents Chemother20024610 3334 333612234875
   PubMed Web of Science ®Google Scholar
• WangYLvYCaiJA novel gene, optrA, that confers transferable resistance to oxazolidinones and phenicols and its presence in Enterococcus faecalis and Enterococcus faecium of human and animal originJ Antimicrob Chemother2015708 2182 219025977397
   PubMed Web of Science ®Google Scholar
• BarberKESmithJRRautARybakMJEvaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolidJ Antimicrob Chemother2016711 152 15526476277
   PubMed Web of Science ®Google Scholar
• ProkocimerPBienPSurberJPhase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infectionsAntimicrob Agents Chemother2011552 583 59221115795
   PubMed Web of Science ®Google Scholar
• ProkocimerPDe AndaCFangEMehraPDasATedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trialJAMA20133096 559 56923403680
   PubMed Web of Science ®Google Scholar
• MoranGJFangECoreyGRDasAFDe AndaCProkocimerPTedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trialLancet Infect Dis2014148 696 70524909499
   PubMed Web of Science ®Google Scholar
• Ortiz-CovarrubiasAFangEProkocimerPGEfficacy, safety, tolerability and population pharmacokinetics of tedizolid, a novel antibiotic, in Latino patients with acute bacterial skin and skin structure infectionsBraz J Infect Dis2016202 184 19226859064
   PubMed Web of Science ®Google Scholar
• BayerEfficacy and safety of intravenous to oral 6-day tedizolid phosphate vs. Intravenous to oral 10-day linezolid in patients with acute bacterial skin and skin structure infection (ABSSSI) Available from: https://clinicaltrials.gov/ct2/show/NCT02066402?term=tr701&rank=26. NLM identifier: NCT02066402Accessed May 1, 2016
   Google Scholar
• SorianoAMiroOMensaJMitochondrial toxicity associated with linezolidN Engl J Med200535321 2305 230616306535
   PubMed Web of Science ®Google Scholar
• NaritaMTsujiBTYuVLLinezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndromePharmacotherapy2007278 1189 119717655517
   PubMed Web of Science ®Google Scholar
• BeekmannSEGilbertDNPolgreenPMToxicity of extended courses of linezolid: results of an Infectious Diseases Society of America Emerging Infections Network surveyDiagn Microbiol Infect Dis2008624 407 41018929458
   PubMed Web of Science ®Google Scholar
• McKeeEEFergusonMBentleyATMarksTAInhibition of mammalian mitochondrial protein synthesis by oxazolidinonesAntimicrob Agents Chemother2006506 2042 204916723564
   PubMed Web of Science ®Google Scholar
• FlanaganSDreskinHProkocimerPComparison of tedizolid and linezolid pharmacokinetics in Phase 1 studies [Abstract A-692]Poster presented at: 54th Interscience Conference on Antimicrobial Agents and ChemotherapySeptember 5–19; 2014Washington, DC
   Google Scholar
• SongTLeeMJeonHSLinezolid trough concentrations correlate with mitochondrial toxicity-related adverse events in the treatment of chronic extensively drug-resistant tuberculosisEBioMedicine2015211 1627 163326870788
   PubMed Web of Science ®Google Scholar
• GouldFKLinezolid: safety and efficacy in special populationsJ Antimicrob Chemother201166Suppl 4 iv3 iv621521705
   PubMed Web of Science ®Google Scholar
• PeaFVialePCojuttiPDel PinBZampariniEFurlanutMTherapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patientsJ Antimicrob Chemother2012678 2034 204222553142
   PubMed Web of Science ®Google Scholar
• FlanaganSMcKeeEEDasDNonclinical and pharmacokinetic assessments to evaluate the potential of tedizolid and linezolid to affect mitochondrial functionAntimicrob Agents Chemother2015591 178 18525331703
   PubMed Web of Science ®Google Scholar
• SchlosserMJHosakoHRadovskyALack of neuropathological changes in rats administered tedizolid phosphate for nine monthsAntimicrob Agents Chemother2015591 475 48125385101
   PubMed Web of Science ®Google Scholar
• MilosevicTPayenVLBrissonLSonveauxPVan VambekeFTulkensPMTedizolid inhibits mitochondrial metabolism and reversibly impairs Cytochrome c-oxydase expression in cultured human cells: impact of a discontinous exposure [Abstract A-974]Poster presented at: 55th Interscience Conference on Antimicrobial Agents and ChemotheraphySeptember 17–21; 2015San Diego, CA
   Google Scholar
• ProkocimerPBienPMuñozKAAsterRHaematological effects of TR-701, linezolid and placebo administered for 21 days in healthy subjects [Abstract A-2069]Poster presented at: 48th Interscience Conference on Antimicrobial Agents and ChemotheraphyOctober 25–28; 2008Washington, DC
   Google Scholar
• FangEDe AndaCDasAProkocimerPSafety and tolerability of tedizolid phosphate, a novel oxazolidinone versus linezolid in two phase III studies in skin/skin structure infections [Abstract PS-295]Poster presented at: 18th Congress of the Asian Pacific Society of RespirologyNovember 11–14; 2013Yokohama, Japan
   Google Scholar
• RybakJMMarxKMartinCAEarly experience with tedizolid: clinical efficacy, pharmacodynamics, and resistancePharmacotherapy20143411 1198 120825266820
   PubMed Web of Science ®Google Scholar
• Morales-MolinaJAMateu-de AntonioJMarin-CasinoMGrauSLinezolid-associated serotonin syndrome: what we can learn from cases reported so farJ Antimicrob Chemother2005566 1176 117816223940
   PubMed Web of Science ®Google Scholar
• ClarkDBAndrusMRByrdDCDrug interactions between linezolid and selective serotonin reuptake inhibitors: case report involving sertraline and review of the literaturePharmacotherapy2006262 269 27616466332
   PubMed Web of Science ®Google Scholar
• FDAFDA drug safety communication: serious CNS reactions possible when linezolid (Zyvox) is given to patients taking certain psychiatric medicationsSilver Spring, MDFDA10212011 Available from: http://www.fda.gov/Drugs/DrugSafety/ucm265305.htmAccessed March 27, 2016
   Google Scholar
• FlanaganSBartizalKMinassianSLFangEProkocimerPIn vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactionsAntimicrob Agents Chemother2013577 3060 306623612197
   PubMed Web of Science ®Google Scholar
• DourosAGrabowskiKStahlmannRDrug-drug interactions and safety of linezolid, tedizolid, and other oxazolidinonesExpert Opin Drug Metab Toxicol20151112 1849 185926457865
   PubMed Web of Science ®Google Scholar
• AntalEJHendershotPEBattsDHSheuWPHopkinsNKDonaldsonKMLinezolid, a novel oxazolidinone antibiotic: assessment of monoamine oxidase inhibition using pressor response to oral tyramineJ Clin Pharmacol2001415 552 56211361052
   PubMed Web of Science ®Google Scholar
• HendershotPEAntalEJWelshmanIRBattsDHHopkinsNKLinezolid: pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HCl, phenylpropanolamine HCl, and dextromethorpan HBrJ Clin Pharmacol2001415 563 57211361053
   PubMed Web of Science ®Google Scholar
• MoelleringRCJrTedizolid: a novel oxazolidinone for gram-positive infectionsClin Infect Dis201458Suppl 1 S1 S324343826
   PubMed Web of Science ®Google Scholar
• FlammRKMendesREHoganPAStreitJMRossJEJonesRNLinezolid surveillance results for the United States (LEADER Surveillance Program 2014)Antimicrob Agents Chemother2016604 2273 228026833165
   PubMed Web of Science ®Google Scholar
• BurdetteSDTrotmanRTedizolid: The first once-daily oxazolidinone class antibioticClin Infect Dis2015618 1315 132126105167
   PubMed Web of Science ®Google Scholar